Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


Intranasal Ketamine for Late-Life Depression and Suicidal Ideation


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT02295787

Organisation Name: Massachusetts General Hospital

Overal Status: Withdrawn

Start Date: July 2015

Last Update: March 3, 2017

Lead Sponsor: Massachusetts General Hospital

Brief Summary: The investigators of this study plan to investigate the feasibility and efficacy of repeated doses of intranasal ketamine in severely depressed patients who are at least 65 years of age and experiencing suicidal ideation. The results of the study could lead to development of new strategies for treating depression.

Conditions:
  • Depression
  • Suicide
  • Suicidal Ideation


Total execution time in seconds: 0.19911694526672